Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MIG Capital: BioNTech Has Transformed Global View Of German Biotech 'But We Don’t Walk On Water’

After BioNTech, German VC Leader Looks To Next Challenge

Executive Summary

MIG Capital’s Matthias Kromayer looks back at the huge success of its long-term backing of BioNTech and discusses the group’s next big life sciences investments, but warns that realism and hard work are needed to achieve another breakthrough.

You may also be interested in...



Investors Back iOmx’s Focus On Tumor Immune Evasion

The German biopharmaceutical company has been around since 2016, but now has the funding to bring its first candidate into clinical trials by late 2022

AC Immune Beefs Up Neurodegenerative Pipeline With AFFiRiS Alpha-Synuclein Portfolio

Deal Snapshot: The company is looking to expand its pipeline beyond Alzheimer’s, where it hit a speedbump in September with the failure of a tau-targeting drug.

Moderna Looks To mRNA To Crack Challenge Of HIV Vaccine

The Bill Gates Foundation-backed partnership with IAVI could bring a HIV vaccine a step closer, but generating the right antibody response has defeated many previous attempts.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145630

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel